- Home
- ABVC vs FGNX Comparison
ABVC vs FGNX Comparison
Compare ABVC & FGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABVC | FGNX |
|---|---|---|
| Founded | 2015 | 1932 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 57.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVC | FGNX |
|---|---|---|
| Price | $1.64 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 56.9K | ★ 89.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $735.18 | $95.83 |
| Revenue Next Year | N/A | $42.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $7.95 |
| 52 Week High | $5.48 | $206.25 |
Technical Indicators
Market Signals| Indicator | ABVC | FGNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 80.89 |
| Support Level | $1.53 | $1.59 |
| Resistance Level | $1.76 | $2.98 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.02 | 0.60 |
| Stochastic Oscillator | 15.79 | 85.37 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.